Visual Abstract

Visual Abstract
Visual Abstract.
View largeDownload slide
Keywords:
Kidney transplantation, Tacrolimus variability, Subtherapeutic levels

Background: Within-patient tacrolimus level variability >30% has been shown to be a risk factor for de novo donor-specific antibody formation and death-censored graft failure among kidney transplant recipients. The burden of tacrolimus variability and the correlation between variability and subtherapeutic tacrolimus levels were examined in a large national data set. Methods: All tacrolimus levels drawn at LabCorp® facilities in the United States with a diagnosis code for kidney transplant between November 2011 and September 2017 were examined, excluding values that could represent new allografts. Tacrolimus variability was calculated if at least 3 levels were available. The percentage of subtherapeutic (<4.0 ng/dL) tacrolimus levels (%subT) was also calculated. Interdependence between %subT and tacrolimus variability was assessed with correlation analysis and linear regression. Results: There were 410,257 tacrolimus levels among 27,375 patients, who had 11 (interquartile range [IQR] 6–20) tacrolimus levels over a median follow-up of 26.5 (IQR 12.8–46.1) months. Median tacrolimus variability was 30.6%, and 51.6% of patients exceeded 30% variability. Median %subT was 11.1% (IQR 0–30.8%), and 34.3% of patients had no subtherapeutic levels. The correlation coefficient between tacrolimus variability and %subT was 0.253 (p< 0.001). In linear regression, tacrolimus variability increased 1.86% for each 10% increase in %subT (p < 0.001), but R-squared for this model was only 0.06. Conclusion: More than half of established kidney transplant patients from a large national sample exhibited levels of tacrolimus variability that have been associated with inferior transplant outcomes. Tacrolimus variability has a weak association with subtherapeutic levels, but represents a more complicated constellation of clinical factors.

Keywords:
Kidney transplantation, Tacrolimus variability, Subtherapeutic levels
1.
Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.
N Engl J Med
. 1999 Dec;341(23):1725–30.
2.
Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Robinson A, et al. OPTN/SRTR 2016 Annual Data Report: kidney.
Am J Transplant
. 2018 Jan;18 Suppl 1:18–113.
3.
O’Regan JA, Canney M, Connaughton DM, O’Kelly P, Williams Y, Collier G, et al. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.
J Nephrol
. 2016 Apr;29(2):269–76.
4.
Rodrigo E, Segundo DS, Fernández-Fresnedo G, López-Hoyos M, Benito A, Ruiz JC, et al. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development.
Transplantation
. 2016 Nov;100(11):2479–85.
5.
Taber DJ, Su Z, Fleming JN, McGillicuddy JW, Posadas-Salas MA, Treiber FA, et al. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.
Transplantation
. 2017 Dec;101(12):2931–8.
6.
Whalen HR, Glen JA, Harkins V, Stevens KK, Jardine AG, Geddes CC, et al. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
Transplantation
. 2017 Feb;101(2):430–6.
7.
Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation.
Nephrol Dial Transplant
. 2010 Aug;25(8):2757–63.
8.
Hsiau M, Fernandez HE, Gjertson D, Ettenger RB, Tsai EW. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation.
Transplantation
. 2011 Oct;92(8):918–22.
9.
Tang JT, Andrews LM, van Gelder T, Shi YY, van Schaik RH, Wang LL, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.
Expert Opin Drug Metab Toxicol
. 2016 May;12(5):555–65.
10.
Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, et al. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
Am J Transplant
. 2018 Apr;18(4):907–15.
11.
Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity.
Clin J Am Soc Nephrol
. 2009 Feb;4(2):481–508.
12.
Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
Clin J Am Soc Nephrol
. 2007 Mar;2(2):374–84.
13.
Shemesh E, Fine RN. Is calculating the standard deviation of tacrolimus blood levels the new gold standard for evaluating non-adherence to medications in transplant recipients?
Pediatr Transplant
. 2010 Dec;14(8):940–3.
14.
Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus.
Clin Pharmacokinet
. 1995 Dec;29(6):404–30.
15.
Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus.
Clin Pharmacokinet
. 2002;41(11):813–51.
16.
Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management.
Transplant Rev (Orlando)
. 2015 Apr;29(2):78–84.
17.
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
Clin Pharmacokinet
. 2004;43(10):623–53.
18.
Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DR. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients.
Am J Transplant
. 2016 Oct;16(10):2954–63.
19.
Gueta I, Markovits N, Yarden-Bilavsky H, Raichlin E, Freimark D, Lavee J, et al. High tacrolimus trough level variability is associated with rejections after heart transplant.
Am J Transplant
. 2018 Oct;18(10):2571–8.
20.
Rayar M, Tron C, Jézéquel C, Beaurepaire JM, Petitcollin A, Houssel-Debry P, et al. High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes.
Transplantation
. 2018 Mar;102(3):e108–14.
21.
Nevins TE, Nickerson PW, Dew MA. Understanding Medication Nonadherence after Kidney Transplant.
J Am Soc Nephrol
. 2017 Aug;28(8):2290–301.
22.
Trofe-Clark J, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, et al. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Am J Kidney Dis
. 2018 Mar;71(3):315–26.
23.
Shuker N, Bouamar R, van Schaik RH, Clahsen-van Groningen MC, Damman J, Baan CC, et al. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
Am J Transplant
. 2016 Jul;16(7):2085–96.
24.
Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing.
Clin Pharmacol Ther
. 2010 Jun;87(6):721–6.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.